Nivolumab (Opdivo®) for classical Hodgkin Lymphoma

Assessment Status Rapid Review Complete
Drug Nivolumab
Brand Opdivo®
Indication As monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.
Assessment Process
Rapid review commissioned 22/11/2016
Rapid review completed 18/01/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

The HSE has approved reimbursement following confidential price negotiations October 2017.